Astute Medical Launches European Sales of Nephrocheck AKI Risk Assessment Test | GenomeWeb

This story originally ran on Oct. 15.

Protein diagnostics firm Astute Medical this week received an EU CE mark for its Nephrocheck acute kidney injury risk assessment test and launched sales of the product in Europe.

The test is the first from the San Diego, Calif.-based firm, and uses two urinary protein biomarkers to assess critically ill patients' risk of developing AKI. The test takes roughly 20 minutes to produce results, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.